Ticagrelor effective at reducing first, as well as recurrent and overall cardiovascular events

March 26, 2012

Ticagrelor, a potent anti-platelet medication, was approved by the Food and Drug Administration in the summer of 2011 and is known to significantly reduce the risk of stroke, heart attack, vascular death and death overall in patients with acute coronary syndromes (ACS), which are characterized by symptoms related to obstruction in coronary arteries, which supply blood to the heart. Now, new research from Brigham and Women's Hospital (BWH) shows that the use of ticagrelor not only reduces the time to a first cardiovascular event (the metric used in most trials) but also significantly reduces the time to a second cardiovascular event or death, and reduces total events including cardiovascular death, heart attack, stroke, ischemic events and urgent revascularization. These findings will be presented at the American College of Cardiology Scientific Sessions on March 25, 2012.

"These data help show both clinicians and patients that if a patient is on ticagrelor and experiences a cardiac event, continued use of this anti-platelet is both safe and effective, and may prevent even more cardiac events than we previously thought" said Payal Kohli, MD a cardiology fellow and BWH researcher in the TIMI Study Group, who is the lead author on this study.

Researchers analyzed data from the PLATO study, where 18,624 patients with ACS were randomly allocated to receive aspirin plus either ticagrelor or clopidogrel. In this cohort of patients, 318 experienced multiple cardiac events during the follow up period. In addition to observing a reduction in the average number of events per patient, and a reduction in total vents, researchers also note that there was no difference in bleeding in patients taking ticagrelor compared to those taking clopidogrel, although the number of bleeding events may have been too small to detect a difference.

"Interestingly, we also found that that those patients who had more cardiac events tended to be older, have a lower body weight and have a higher number of cardiovascular risk factors. There were also a higher proportion of females in this group." Kohli said.

Explore further: New study suggests potent antiplatelet drug effective with low-dose aspirin

Related Stories

Recommended for you

Smoking leaves lasting marks on DNA, study finds

September 20, 2016

(HealthDay)—Smoking cigarettes can leave a lasting imprint on human DNA, altering more than 7,000 genes in ways that may contribute to the development of smoking-related diseases, a new study says.

Sleep disorders may influence heart disease risk factors

September 20, 2016

Sleep problems including sleeping too little or too long, may be linked to a variety of factors that may raise the risk for cardiovascular diseases, according to a new American Heart Association scientific statement published ...

Sleep troubles, heart troubles?

September 20, 2016

(HealthDay)—Sleep disorders—including too little or too much sleep—may contribute to heart disease risk factors, the American Heart Association said in its first statement on the risks of sleep problems.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.